A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

An Open-label Study to Assess the Safety, Efficacy and Absorption of Exodif™ (Tolevamer Potassium Sodium) Tablets in Patients With Clostridium Difficile-Associated Diarrhea

Approximately 65 patients will be entered into this study taking place in North America. The aim of this study is to evaluate the safety, efficacy and absorption of an investigational drug in patients with C. difficile-associated diarrhea (CDAD). All study related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is 6 weeks.

Inclusion Criteria:

• The presence of CDAD at the time of enrollment
• Negative serum pregnancy test (HCG) for women of childbearing potential.

Exclusion Criteria:

• Any contraindication to oral / enteral therapy including fulminant C. difficile disease.
• Any acutely life-threatening medical conditions.
• Acute or chronic diarrhea of other cause.